Evidence map›Paper›PMID 33430079›Full record

ArticleNanomaterials (Basel, Switzerland)2021

α

Marc Pretze, Valeska von Kiedrowski, Roswitha Runge, Robert Freudenberg, René Hübner, Güllü Davarci, Ralf Schirrmacher, Carmen Wängler, Björn Wängler

Open access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Preclinical Evaluation of Stable Integrin αPharmaceuticals (Basel, Switzerland) · 2025
    Article
  2. Peptide-Based Biomaterials as a Promising Tool for Cancer Radiotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  3. Article
  4. Radiosynthesis of StablePharmaceuticals (Basel, Switzerland) · 2023
    Article
  5. Observation of the protein expression levelFrontiers in chemistry · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Marc PretzeDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany.
Valeska von KiedrowskiMolecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, 68167 Mannheim, Germany.
Roswitha RungeDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany.
Robert FreudenbergDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany.
René HübnerHelmholtz-Zentrum Dresden-Rossendorf, Institute of Ion Beam Physics and Materials Research, 01328 Dresden, Germany.
Güllü DavarciMolecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, 68167 Mannheim, Germany.
Ralf SchirrmacherDepartment of Oncology, Division of Oncological Imaging, University of Alberta, Edmonton, AB T6G 2R3, Canada.ORCID 0000-0002-7098-3036
Carmen WänglerBiomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, 68167 Mannheim, Germany.ORCID 0000-0003-1161-8669
Björn WänglerMolecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, 68167 Mannheim, Germany.
Heidelberg University · DEUniversity Hospital Carl Gustav Carus · DEHelmholtz-Zentrum Dresden-Rossendorf · DEUniversity of Alberta · CA

Funding

German Federal Ministry of Education and Research (BMBF) within the Framework "Forschungscampus: public-private partnership for Innovations" 13GW0091B, 13GW0091E, 13GW0388A and 13GW0389B
6 · The paper itself

Abstract

This paper reports on the development of tumor-specific gold nanoparticles (AuNPs) as theranostic tools intended for target accumulation and the detection of tumor angiogenesis via optical imaging (OI) before therapy is performed, being initiated via an external X-ray irradiation source. The AuNPs were decorated with a near-infrared dye, and RGD peptides as the tumor targeting vector for α

Indexed as

gold nanoparticleoptical imagingradiosensitizerRGD peptidetumor angiogenesis

Identifiers

PMID33430079
PMCPMC7827626
OpenAlexW3120419258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.